文献速递肾癌与肾肿瘤

索拉非尼剂量递增用于初治转移性肾细胞癌:一项非随机、开放标签、2b期研究

Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
PubMed 文献 · BJU Int · 2017-01-09

这项非随机开放标签2b期研究评估初治转移性肾细胞癌患者索拉非尼剂量递增的疗效与安全性。83例患者初始接受索拉非尼400 mg每日两次,计划两次递增(每次增加200 mg每日两次)。改良意向治疗人群客观缓解率为44.4%(8/18,95%CI 21.5-69.2),意向治疗人群为17.9%(12/67,95%CI 9.6-29.2),中位无进展生存期7.4个月(95%CI 6.0-11.7)。

要点

  • 83例初治转移性肾细胞癌患者接受索拉非尼治疗,初始剂量400 mg每日两次。
  • 改良意向治疗人群客观缓解率44.4%(8/18,95%CI 21.5-69.2),意向治疗人群17.9%(12/67,95%CI 9.6-29.2)。
  • 中位无进展生存期7.4个月(95%CI 6.0-11.7),最常见不良事件为手足皮肤反应(66.3%)和腹泻(63.9%)。

核心结论

  • 索拉非尼在初治转移性肾细胞癌患者中显示出临床获益,但能维持超过400 mg每日两次剂量的患者相对较少。
  • 有证据表明,在可耐受的情况下,从标准索拉非尼剂量递增可能增强临床获益。
  • 然而,本研究不支持对大多数初治转移性肾细胞癌患者进行剂量递增。
  • 可探索索拉非尼剂量递增的替代方案。

研究设计与样本

  • 非随机、开放标签、2b期研究,纳入初治转移性肾细胞癌患者83例。
  • 患者初始接受索拉非尼标准口服剂量400 mg每日两次。
  • 计划两次剂量递增,每次在前一剂量水平治疗28天后增加200 mg每日两次。
  • 通过剂量降低、中断或延迟递增来管理不良事件。
  • 主要终点为改良意向治疗人群的客观缓解率,该人群包括治疗≥6个月且其中≥4个月在最高耐受剂量下治疗的患者。

主要发现

  • 最长持续时间接受的剂量为400、600和800 mg每日两次的患者分别占48.2%、15.7%和24.1%。
  • 改良意向治疗人群客观缓解率为44.4%(n=8/18;95%CI 21.5-69.2)。
  • 意向治疗人群客观缓解率为17.9%(n=12/67;95%CI 9.6-29.2)。
  • 意向治疗人群中位无进展生存期为7.4个月(95%CI 6.0-11.7)。
  • 任何级别最常见不良事件为手足皮肤反应(66.3%)和腹泻(63.9%)。

局限性

  • 本研究为非随机、开放标签设计。
  • 本研究不支持对大多数初治转移性肾细胞癌患者进行剂量递增。
  • 可探索索拉非尼剂量递增的替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of sorafenib dose escalation in metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: Intra-patient dose escalation may enhance the clinical benefit of targeted anticancer agents in metastatic disease. In this non-randomised, open-label, Phase 2b study, treatment-naïve patients with mRCC were initially treated with the standard oral sorafenib dose [400 mg twice daily (BID)]. Two dose escalations were planned, each 200 mg BID after 28 days at the prior level. Dose reductions, interruptions, or delayed escalations were used to manage adverse events (AEs). The primary endpoint was objective response rate (ORR) in the modified intent-to-treat (mITT) population, which comprised patients with ≥6 months of treatment including ≥4 months of therapy at their highest tolerated dose. Secondary endpoints included progression-free survival (PFS) and safety. RESULTS: In all, 83 patients received sorafenib. The dose received for the longest duration was 400, 600, and 800 mg BID in 48.2%, 15.7%, and 24.1% of patients, respectively. The ORR was 44.4% [n = 8/18; 95% confidence interval (CI) 21.5-69.2] and 17.9% (n = 12/67; 95% CI 9.6-29.2) in the mITT and ITT populations, respectively. The median (95% CI) PFS was 7.4 (6.0-11.7) months (ITT). The most common AEs of any grade were hand-foot skin reaction (66.3%) and diarrhoea (63.9%). CONCLUSION: Sorafenib demonstrated clinical benefit in treatment-naïve patients with mRCC. However, relatively few patients could sustain doses of >400 mg BID. There was evidence that, where tolerated, escalation from the standard sorafenib dose may have enhanced clinical benefit. However, this study does not support dose escalation for most patients with treatment-naïve mRCC. Alternative protocols for sorafenib dose escalation could be explored.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Gore ME, Jones RJ, Ravaud A, et al. Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. BJU Int. 2017. PMID: 27981711. doi:10.1111/bju.13740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。